AVENIO Tumor Tissue Analysis Kits are a portfolio of NGS assays that provide in-house tumor profiling, comprehensive genomic profiling (CGP), and surveillance & monitoring for clinical research. Through an optimized, end-to-end workflow, the kits offer a versatile solution to evaluate DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue samples.
Designed to match the content of the 324 gene FoundationOne® CDx panel, the assay detects four classes of genomic alterations as well as genomic signatures: TMB, MSI, LOH.
A 17 gene (81kb) pan-cancer assay that contains guideline-aligned biomarkers, including those identified by the U.S. National Comprehensive Cancer Network (NCCN).2
A 77 gene (192kb) pan-cancer assay that contains 17 genes in the NCCN and other guidelines, plus 60 emerging biomarkers investigated in clinical research.
A 197 gene (198kb) assay, containing 17 NCCN guideline-aligned genes, plus 471 frequently mutated disease-associated regions across 197 genes; optimized for longitudinal monitoring of tumor burden in lung and colorectal cancer.